Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria: * Newly diagnosed AML defined according to the World Health Organization (WHO)-classification (excluding acute promyelocytic leukemia \[APL\]) * Ages 18-60 years * Written informed consent of each patient at study entry. * Molecular and cytogenetical diagnostics on initial bone marrow and peripheral blood specimen at the central reference laboratories Exclusion Criteria: * Bleeding independent of the AML * Acute promyelocytic leukemia * Uncontrollable infection * Participation in a concurrent clinical study * Insufficiency of the kidneys (creatinine \> 1.5x upper normal serum level), of the liver (bilirubin, AST or AP \> 2x upper normal serum level), severe obstructive or restrictive ventilation disorder, heart failure New York Heart Association (NYHA) III/IV * Severe neurological or psychiatric disorder interfering with ability to give an informed consent. * No consent for registration, storage and processing of the individual disease-characteristics and course. * Performance status WHO \> 2 * Pregnancy